The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine. The agency’s decision, which Moderna announced in a press ...

The U.S. Food and Drug Administration has reversed an earlier decision and said it will review drugmaker Moderna's application for approval of a seasonal flu vaccine, the company said in a statement ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna met with FDA officials after the agency initially rejected its application for a new mRNA flu vaccine. - Sarah ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna's mRNA flu ...

Six years after COVID ripped this nation apart, we still don’t know what the truth is. Fauci's diary doesn't help. Quarterback Aaron Rodgers is set to play his last NFL season for the Pittsburgh ...

Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.

Investors should note that in February, the FDA issued a refusal-to-file letter regarding Moderna’s influenza vaccine, citing the choice of a standard-dose seasonal influenza vaccine as the sole ...

A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same mRNA technology that was key to ending the ...

WASHINGTON — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food ...

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...